LLY compared with PTGX: revenue, margins and what each company keeps, and the suppliers and customers both name

LLYELI Lilly & Co

Mkt capRevenueRevenue

PTGXProtagonist Therapeutics, Inc

Mkt capRevenueRevenue

Compare

LLYELI Lilly & Co

PTGXProtagonist Therapeutics, Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

LLY

3 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±5.1%▲+6.63%×1.29

Q2 FY26±6.2%▲+4.86%×0.79

Q1 FY26±5.3%▲+9.80%×1.85

Feb 4 '26±6.1%▲+10.33%×1.69

PTGX

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26thin chain±8.1%▼−2.38%×0.30

Q2 FY26±11.8%▲+6.45%×0.55

= impliedLLY realized, solidPTGX realized, hatchedOne scale, both sides: full bar = 12%× = |realized| ÷ impliedSource: market data

May 6 '26±5.3%▲+4.80%×0.91

Q1 FY26±9.0%▲+1.48%×0.17

LLYELI Lilly & Co

1,360.90▼−0.28%· post 1,358.90

Mkt cap$1.2TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

PTGXProtagonist Therapeutics, Inc

132.31▼−2.18%· post 132.31

ClosedNov 6 '26

Mkt cap$8.6BRevenue$274MQ3 FY26Revenue$46MFY25

Compare

ClosedNov 6 '26

LLYELI Lilly & Co

PTGXProtagonist Therapeutics, Inc

1,360.90▼−0.28%post 1,358.90

Price

132.31▼−2.18%post 132.31

$1.2T

Mkt cap

$8.6B

Q3 FY26$24.4B

Revenue

$274MQ3 FY26

FY25$65.2B

Revenue

$46MFY25

LLY1,360.90▼−0.28%vsPTGX132.31▼−2.18%ClosedNov 6 '26